64.83
0.40 (0.62%)
| Previous Close | 64.43 |
| Open | 64.25 |
| Volume | 2,167,577 |
| Avg. Volume (3M) | 3,609,296 |
| Market Cap | 14,447,041,536 |
| Price / Earnings (TTM) | 27.24 |
| Price / Earnings (Forward) | 15.08 |
| Price / Sales | 3.92 |
| Price / Book | 3.16 |
| 52 Weeks Range | |
| Earnings Date | 28 Jul 2025 - 1 Aug 2025 |
| Profit Margin | 13.83% |
| Operating Margin (TTM) | 22.17% |
| Diluted EPS (TTM) | 2.38 |
| Quarterly Revenue Growth (YOY) | -1.20% |
| Quarterly Earnings Growth (YOY) | -18.50% |
| Total Debt/Equity (MRQ) | 54.80% |
| Current Ratio (MRQ) | 3.24 |
| Operating Cash Flow (TTM) | 1.13 B |
| Levered Free Cash Flow (TTM) | 775.88 M |
| Return on Assets (TTM) | 6.92% |
| Return on Equity (TTM) | 11.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Bearish |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | Hologic, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 0.86% |
| % Held by Institutions | 102.61% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 87.00 (RBC Capital, 34.20%) | Buy |
| Median | 70.00 (7.98%) | |
| Low | 68.00 (Evercore ISI Group, 4.89%) | Hold |
| Average | 74.00 (14.15%) | |
| Total | 3 Buy, 3 Hold | |
| Avg. Price @ Call | 65.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 06 Aug 2025 | 87.00 (34.20%) | Buy | 66.89 |
| Morgan Stanley | 31 Jul 2025 | 69.00 (6.43%) | Hold | 66.82 |
| UBS | 31 Jul 2025 | 70.00 (7.97%) | Hold | 66.82 |
| Mizuho | 16 Jul 2025 | 70.00 (7.97%) | Buy | 63.86 |
| Citigroup | 09 Jul 2025 | 80.00 (23.40%) | Buy | 65.85 |
| Evercore ISI Group | 08 Jul 2025 | 68.00 (4.89%) | Hold | 64.90 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Jul 2025 | Announcement | Hologic Announces Financial Results for Third Quarter of Fiscal 2025 |
| 02 Jul 2025 | Announcement | Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025 |
| 22 May 2025 | Announcement | Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |